Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e48–e50. doi: 10.1097/QAI.0000000000000990

Figure 1.

Figure 1

Proportion of study participants (A-dark gray EFV/FTC/TDF and B-light gray RAL+LPV/r) with an undetectable HIV viral load over time ignoring the missing RNA measurements due to early study discontinuation between week 4 and week 48. Significant difference are noted between arms at week 4 (with a higher proportion of persons in the RAL+LPV/r arm achieving an undetectable HIV viral load) but no difference is observed at week 48.